Key result
Amiodarone, beta-blockers, and calcium channel blockers yield highly variable rhythm control efficacy in critically ill NOAF.
Why the study?
The study was conducted to summarise the latest evidence on the efficacy and safety of treatments for new-onset atrial fibrillation in critical illness.
What is the efficacy and safety of pharmacological treatments for new-onset atrial fibrillation in critically ill adult patients?
Systematic Review (n=16)
What is the efficacy and safety of pharmacological treatments for new-onset atrial fibrillation in critically ill adult patients?
Answers are grounded in this paper and cite their sources.
The efficacy of various pharmacological agents for rhythm control in critically ill patients with new-onset atrial fibrillation is highly variable, highlighting the need for high-quality comparative trials.
OBJECTIVES: The aim of this review is to summarise the latest evidence on efficacy and safety of treatments for new-onset atrial fibrillation (NOAF) in critical illness. PARTICIPANTS: Critically ill adult patients who developed NOAF during admission. PRIMARY AND SECONDARY OUTCOMES: Primary outcomes were efficacy in achieving rate or rhythm control, as defined in each study. Secondary outcomes included mortality, stroke, bleeding and adverse events. METHODS: We searched MEDLINE, EMBASE and Web of Knowledge on 11 March 2019 to identify randomised controlled trials (RCTs) and observational studies reporting treatment efficacy for NOAF in critically ill patients. Data were extracted, and quality assessment was performed using the Cochrane Risk of Bias Tool, and an adapted Newcastle-Ottawa Scale. RESULTS: Of 1406 studies identified, 16 remained after full-text screening including two RCTs. Study quality was generally low due to a lack of randomisation, absence of blinding and small cohorts. Amiodarone was the most commonly studied agent (10 studies), followed by beta-blockers (8), calcium channel blockers (6) and magnesium (3). Rates of successful rhythm control using amiodarone varied from 30.0% to 95.2%, beta-blockers from 31.8% to 92.3%, calcium channel blockers from 30.0% to 87.1% and magnesium from 55.2% to 77.8%. Adverse effects of treatment were rarely reported (five studies). CONCLUSION: The reported efficacy of beta-blockers, calcium channel blockers, magnesium and amiodarone for achieving rhythm control was highly varied. As there is currently significant variation in how NOAF is managed in critically ill patients, we recommend future research focuses on comparing the efficacy and safety of amiodarone, beta-blockers and magnesium. Further research is needed to inform the decision surrounding anticoagulant use in this patient group.
No takes yet. Share an insight, caveat, or question.
O’Bryan et al. (2020) conducted a systematic review in New-onset atrial fibrillation in critical illness (n=16). Amiodarone, beta-blockers, calcium channel blockers, magnesium was evaluated on Efficacy in achieving rate or rhythm control. Efficacy for achieving rhythm control in critically ill patients with NOAF varied widely, ranging from 30.0-95.2% for amiodarone, 31.8-92.3% for beta-blockers, and 30.0-87.1% for calcium channel blockers.
Synapse has enriched 10 related papers. Consider them for comparative context: